Literature DB >> 26473781

Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice.

Masashi Fujimoto1, Masato Shiba1, Fumihiro Kawakita1, Lei Liu1, Naoshi Shimojo2,3, Kyoko Imanaka-Yoshida2,3, Toshimichi Yoshida2,3, Hidenori Suzuki1,3.   

Abstract

OBJECT Tenascin-C (TNC), a matricellular protein, is induced in the brain following subarachnoid hemorrhage (SAH). The authors investigated if TNC causes brain edema and blood-brain barrier (BBB) disruption following experimental SAH. METHODS C57BL/6 wild-type (WT) or TNC knockout (TNKO) mice were subjected to SAH by endovascular puncture. Ninety-seven mice were randomly allocated to WT sham-operated (n = 16), TNKO sham-operated (n = 16), WT SAH (n = 34), and TNKO SAH (n = 31) groups. Mice were examined by means of neuroscore and brain water content 24-48 hours post-SAH; and Evans blue dye extravasation and Western blotting of TNC, matrix metalloproteinase (MMP)-9, and zona occludens (ZO)-1 at 24 hours post-SAH. As a separate study, 16 mice were randomized to WT sham-operated, TNKO sham-operated, WT SAH, and TNKO SAH groups (n = 4 in each group), and activation of mitogen-activated protein kinases (MAPKs) was immunohistochemically evaluated at 24 hours post-SAH. Moreover, 40 TNKO mice randomly received an intracerebroventricular injection of TNC or phosphate-buffered saline, and effects of exogenous TNC on brain edema and BBB disruption following SAH were studied. RESULTS Deficiency of endogenous TNC prevented neurological impairments, brain edema formation, and BBB disruption following SAH; it was also associated with the inhibition of both MMP-9 induction and ZO-1 degradation. Endogenous TNC deficiency also inhibited post-SAH MAPK activation in brain capillary endothelial cells. Exogenous TNC treatment abolished the neuroprotective effects shown in TNKO mice with SAH. CONCLUSIONS Tenascin-C may be an important mediator in the development of brain edema and BBB disruption following SAH, mechanisms for which may involve MAPK-mediated MMP-9 induction and ZO-1 degradation. TNC could be a molecular target against which to develop new therapies for SAH-induced brain injuries.

Entities:  

Keywords:  BBB = blood-brain barrier; DCI = delayed cerebral ischemia; EBI = early brain injury; ERK = extracellular signal-regulated kinase; ICA = internal carotid artery; JNK = c-Jun N-terminal kinase; MAPK = mitogen-activated protein kinase; MMP = matrix metalloproteinase; PBS = phosphate-buffered saline; PDGF = platelet-derived growth factor; SAH = subarachnoid hemorrhage; TNC = tenascin-C; TNKO = TNC knockout; WT = wild-type; ZO = zona occludens; blood-brain barrier disruption; brain edema; early brain injury; knockout mice; subarachnoid hemorrhage; tenascin-C; vascular disorders

Mesh:

Substances:

Year:  2015        PMID: 26473781     DOI: 10.3171/2015.4.JNS15484

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  40 in total

Review 1.  Mechanisms of neuroinflammation and inflammatory mediators involved in brain injury following subarachnoid hemorrhage.

Authors:  Takeshi Okada; Hidenori Suzuki
Journal:  Histol Histopathol       Date:  2020-02-06       Impact factor: 2.303

Review 2.  Neurobehavioral testing in subarachnoid hemorrhage: A review of methods and current findings in rodents.

Authors:  Nefize Turan; Brandon A Miller; Robert A Heider; Maheen Nadeem; Iqbal Sayeed; Donald G Stein; Gustavo Pradilla
Journal:  J Cereb Blood Flow Metab       Date:  2016-10-01       Impact factor: 6.200

3.  The role of the lectin-like oxLDL receptor (LOX-1) in traffic-generated air pollution exposure-mediated alteration of the brain microvasculature in Apolipoprotein (Apo) E knockout mice.

Authors:  JoAnn Lucero; Usa Suwannasual; Lindsay M Herbert; Jacob D McDonald; Amie K Lund
Journal:  Inhal Toxicol       Date:  2017-08-17       Impact factor: 2.724

Review 4.  Brain endothelial cell junctions after cerebral hemorrhage: Changes, mechanisms and therapeutic targets.

Authors:  Richard F Keep; Anuska V Andjelkovic; Jianming Xiang; Svetlana M Stamatovic; David A Antonetti; Ya Hua; Guohua Xi
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-08       Impact factor: 6.200

5.  Plasma Periostin and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Hideki Kanamaru; Fumihiro Kawakita; Fumi Nakano; Yoichi Miura; Masato Shiba; Ryuta Yasuda; Naoki Toma; Hidenori Suzuki
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 6.  Combined bioscaffold with stem cells and exosomes can improve traumatic brain injury.

Authors:  Jiaying Yuan; Benson O A Botchway; Yong Zhang; Xizhi Wang; Xuehong Liu
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

7.  Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Hidenori Suzuki; Yoshinari Nakatsuka; Ryuta Yasuda; Masato Shiba; Yoichi Miura; Mio Terashima; Yume Suzuki; Koichi Hakozaki; Fuki Goto; Naoki Toma
Journal:  Transl Stroke Res       Date:  2018-07-23       Impact factor: 6.829

8.  Deficiency of Tenascin-C Alleviates Neuronal Apoptosis and Neuroinflammation After Experimental Subarachnoid Hemorrhage in Mice.

Authors:  Lei Liu; Masashi Fujimoto; Fumi Nakano; Hirofumi Nishikawa; Takeshi Okada; Fumihiro Kawakita; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; Hidenori Suzuki
Journal:  Mol Neurobiol       Date:  2018-03-15       Impact factor: 5.590

9.  Anti-Vascular Endothelial Growth Factor Treatment Suppresses Early Brain Injury After Subarachnoid Hemorrhage in Mice.

Authors:  Lei Liu; Masashi Fujimoto; Fumihiro Kawakita; Fumi Nakano; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; Hidenori Suzuki
Journal:  Mol Neurobiol       Date:  2015-08-21       Impact factor: 5.590

Review 10.  Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity.

Authors:  Anna M Marzeda; Kim S Midwood
Journal:  J Histochem Cytochem       Date:  2018-01-31       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.